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During the past decade, tremendous interest has arisen in the use of nonoperative therapies for patients with
non–small cell lung cancer. Of these therapies, stereotactic body radiotherapy has become established as an ef-
fective modality for treating peripheral cancer in medically inoperable patients. Toxicity is low, and the treat-
ment is effective, with excellent local control rates. Several investigators have suggested that stereotactic
body radiotherapy could be effective for high-risk operable patients (usually treated with sublobar resection)
and even perhaps for standard-risk operable patients (usually treated with lobectomy); however, this is less ac-
cepted. A direct comparison of stereotactic body radiotherapy and sublobar resection is difficult for a number of
reasons. These include different definitions of recurrence, different populations of patients in these studies (with
those undergoing stereotactic body radiotherapy tending to be the medically inoperable group), and different
methods of classifying morbidity in the surgical and radiation oncology studies. Imaging follow-up has also
not been standardized among the studies. Thus, a randomized study is necessary and timely. Investigators
from the American College of Surgeons Oncology Group and the Radiation Therapy and Oncology Group
have collaborated to develop a phase III randomized study comparing stereotactic body radiotherapy and sub-
lobar resection (with or without brachytherapy) for high-risk operable patients with non–small cell lung cancer.
This study (American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021)
has recently opened for accrual. It is hoped that this will help to better define the role of these therapies for pa-
tients with non–small cell lung cancer. (J Thorac Cardiovasc Surg 2012;144:S35-8)In general, patients with stage I non–small cell lung cancer
(NSCLC) can be classified into 3 groups: standard-risk pa-
tients who are usually treated with lobectomy, high-risk oper-
able patients who are usually treated with sublobar resection
(SR), and medically inoperable patients who are considered
too high risk for surgery and are usually treated with external
beam radiotherapy or 1 of the newer approaches for lung can-
cer such as stereotactic body radiotherapy (SBRT) or radio-
frequency ablation.1-4 During the past decade, there has
been significant interest in these alternative approaches to
surgery, in particular with the use of SBRT.
There has been tremendous success in the development
of SBRT. The initial studies focused on the safety and fea-
sibility of SBRT for patients with lung cancer.5,6
One problemwhen interpreting these studies has been the
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The Journal of Thoracic and Cathe different protocols used to treat NSCLC at different cen-
ters. Currently, from the work from the Indiana University
and the Radiation Therapy and Oncology Group, a dose
of 54 Gy in 3 fractions has been established as optimal
for the treatment of peripheral NSCLC using SBRT.3,7
A common theme in the reports of SBRT has been that of
excellent primary tumor control, even approaching that of lo-
bectomy.8-10 This has led some investigators to suggest that
SBRT might be preferable to surgical resection, in
particular, to SR, because of the increased incidence of local
recurrence reported with resections less than lobectomy.1
This has led to the development of a randomized study
that recently opened for accrual. The study is being under-
taken by investigators from both the American College of
Surgeons Oncology Group (ACOSOG) and the Radiation
Therapy Oncology Group. We provide a brief overview of
the ACOSOG Z4099/Radiation Therapy Oncology Group
1021 study and its importance to physicians treating pa-
tients with NSCLC.BACKGROUND
There are a number of considerations when comparing 2
very different approaches such as SR and SBRT for treating
localized NSCLC, particularly when applied to patients
who are at greater than average risk of undergoing surgery.
These include oncologic concerns such as recurrence and
survival, differences in morbidity between these therapies,rdiovascular Surgery c Volume 144, Number 3 S35
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ACOSOG ¼ American College of Surgeons
Oncology Group
AE ¼ adverse event
NSCLC ¼ non–small cell lung cancer
SBRT ¼ stereotactic body radiotherapy
SR ¼ sublobar resection6 The Jourthe ability to deliver the therapy uniformly (which is of par-
ticular significance for SBRT), and the effect of these ther-
apies on a patient’s quality of life.
Although SBRT has been reported to have excellent local
control rates, it must be remembered that the definitions of
recurrence have been dissimilar between the surgical and
SBRT series. In the surgical data, local recurrence usually
includes recurrence occurring within the same lobe as the
SR and, sometimes, another lobe within the ipsilateral
lung, as well as recurrence within the hilar and, sometimes,
ipsilateral mediastinal lymph nodes.2,11,12 In the SBRT
data, local recurrence is usually synonymous with primary
tumor control only.13-15 From a surgical standpoint, if
a complete resection has been achieved, the only form of
recurrence that would be equivalent to failed primary
tumor control would be staple line recurrence. For the
ACOSOG Z4099 study, a uniform classification for local
recurrence will be used, defining local recurrence as
a confirmed post-treatment tumor appearing at the primary
site, the staple line or chest wall, or within the involved lobe.
In addition, specified realms of regional recurrence and dis-
tant progression will be collected. This will help us to better
understand the differences and similarities between SR and
SBRTwith respect to the recurrence patterns and to identify
the general strengths and weaknesses of each therapy.
It is often difficult to definitively diagnose local recur-
rence when it is suspected. Technical and patient chal-
lenges exist to obtaining a tissue diagnosis. Additionally,
it could be that the presence of recurrence could be of
less significance in a higher risk patient with medical co-
morbidities. Thus, the primary endpoint of the study is
the 3-year overall survival. Previous studies of SR have in-
volved both standard-risk and high-risk operable patients,
with survival for stage I patients appearing to be 60% to
90% after SR. SBRT studies have generally involved med-
ically inoperable patients but have also included high-risk
operable patients.10,16 Overall survival appears to be
about 55% at 3 years.
Another factor to consider is that the patient populations
in SBRT and SR studies that have previously been reported
are clearly dissimilar. The advantage of a randomized
study such as the ACOSOG Z4099 is that the patientsnal of Thoracic and Cardiovascular Surgwill be similar in terms of their comorbid disease and
surgical risk.
Intuitively, patients undergoing SBRT should have lower
morbidity than patients undergoing SR, and, certainly, a re-
view of previous studies would suggest that this is the case.
However, a few caveats should be considered. With SR, the
complications will typically occur early. With SBRT, the
complications will usually occur later, even months and
years after therapy. Many surgical series did not use the
Common Terminology Criteria for Adverse Events version
when reporting morbidity.17 The Common Terminology
Criteria is a broad classification of adverse events (AEs)
with several defined categories. Within each category, the
AEs are listed and accompanied by a description of severity
(or grade). Grade 1 is mild, grade 2 moderate, grade 3 se-
vere, grade 4 life-threatening or disabling, and grade 5,
death related to the AE. Typically, grade 3 and greater com-
plications are reported in oncologic studies. The ACOSOG
recently reported the incidence of grade 3 and greater AEs
from another study of 224 patients with high-risk lung can-
cer undergoing SR.18 Grade 3 or greater AEs occurred in 62
(29.7%) of 222 patients eligible for analysis at 30 days.
Perioperative mortality occurred in 3 (1.4%) of 222 pa-
tients. In comparison, in a phase II study of 55 patients
treated with SBRT, grade 3 and 4 AEs occurred in 16%
of the patients. No grade 5 toxicities occurred in that study.
In the ACOSOG Z4099 study, AEs will be recorded using
the Common Toxicity Criteria classification and will be
monitored throughout the follow-up period. It might be pos-
sible when ACOSOG Z4099 is eventually completed to
identify groups of patients who might be more appropri-
ately treated with 1 approach or another because of their
risk profile. For instance, in the recently completed ACO-
SOG study of SR, grade 3 AEs were more likely to occur
in patients with a diffusing capacity of carbon dioxide of
46% or less.18
STUDY OVERVIEW
The ACOSOG Z4099 is a randomized phase III study
that will compare SR and SBRT for high-risk operable pa-
tients with NSCLC. Eligible patients will have clinical stage
I diseasewith tumors 3 cm or less in the maximum diameter.
Invasive lymph node staging will not be mandatory for all
patients. Only those patients with clinically suspicious
lymph nodes (defined as>1 cm on short axis by computed
tomography and/or positive by positron emission tomogra-
phy) will require biopsy before registration to confirm N0
status. Biopsy methods can include mediastinoscopy, ante-
rior mediastinotomy, endoscopic ultrasonography, endo-
bronchial ultrasonography, computed tomography-guided
techniques, and video-assisted thoracic surgical biopsy. It
is possible that in the surgical arm of the study the disease
of some patients will be upstaged. However, the primary
analysis will be an ‘‘intent-to-treat’’ analysis, and allery c September 2012
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analysis.
The tumor will need to be in a location that will permit
sublobar resection and also not be within 2 cm of the
proximal bronchial tree in all directions. Tumors in close
proximity to the bronchial tree have previously been dem-
onstrated to have a high incidence of grade 4 and 5 toxicity
with standard-dose SBRT.7 Additionally, tissue diagnosis
confirming NSCLC will be required for all patients before
registration.
Eligible patients will be defined as high risk using the
same criteria used for ACOSOG Z4032.18,19 ACOSOG
Z4032 was a randomized study undertaken to compare
SR alone with SR plus brachytherapy for stage I lung
cancer. Although closed to accrual, the primary endpoint
data for ACOSOG Z4032 is not yet available; thus, it is
unclear whether the use of brachytherapy should be
routinely recommended. For this reason, brachytherapy is
not a requirement in the surgical arm of ACOSOG Z4099,
and the decision to use brachytherapy will be determined
by institutional preference.
The primary endpoint for the study will be the 3-year
overall survival. The secondary endpoints will include com-
parisons of locoregional recurrence (using a uniform defini-
tion), disease-free survival, grade 3 or greater AEs during
a 1-year period, the effect of therapy on pulmonary func-
tion, and a comparison of AEs and pulmonary function
test results in patients with a high or low Charlson comor-
bidity index.
In addition, some correlative studies will be undertaken
to consider patients’ quality of life, and molecular studies
using tissue obtained at resection and blood. The target ac-
crual for ACOSOG Z4099 is 420 patients.
CONCLUSIONS AND CHALLENGES
Amajor challengewhen undertaking a study using 2 ther-
apies with very different toxicity profiles is to ask a patient
to consider randomization to 1 of these approaches. Addi-
tionally, physicians could have their own biases regarding
what they believe is the optimal therapy. The study will re-
quire commitment by investigators as theymeet and council
their patients and close collaboration between surgeons and
radiation oncologists. It is likely that longer and more de-
tailed consultations will be required compared with simply
presenting a plan for therapy.
Surgeons understand that the extent of resection can af-
fect ultimate control. As such, not all SRs are the same. Seg-
mentectomy or wide wedge resection is probably superior
to close wedge resection. If no lymph nodes are removed,
it might be that a close wedge would not be that different
from SBRT. In contrast, the results of SBRT have continued
to be encouraging. Local control (using nonsurgical defini-
tions) has been excellent and the morbidity almost certainly
lower. Because the cancer is not removed with SBRT, serialThe Journal of Thoracic and Caimaging will be needed to search for areas of new growth or
persistent disease within the scar left after SBRT. An issue
when interpreting the results of earlier studies of SBRT is
that these were often undertaken in medically inoperable
patients with significant comorbid disease. Such patients
can die from noncancer-related causes before any coexist-
ing locally recurrent cancer is identified. Thus, in the ab-
sence of a randomized study, it would not be appropriate
to apply SBRT to patients with better risk.
The time for the ACOSOG Z4099 study is now. If a ran-
domized study is not undertaken, it is possible that very ef-
fective surgery will be relegated to a salvage option for
patients inwhomSBRT fails, whichwould likely be a disser-
vice to our patients. We believe that the optimal patients to
undertake the ACOSOG Z4099 study would be those be-
lieved to be in the high-risk surgical category, for which
physicians are more likely to have equipoise and be willing
to randomize their patients. A less-invasive approach can be
justified for these patients, because this should allow for bet-
ter quality of life and lower morbidity but, perhaps, at a cost
of poorer cancer control. Careful documentation of the risk
factors such as the Charlson comorbidity index, pulmonary
function, and tumor size, could also help us to define the
subgroups that would benefit from 1 approach or another.References
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